Maria Palasis
About Maria Palasis
Maria Palasis serves as a Board Member and has held the position of President, CEO, and Board Director at Lyra Therapeutics since 2018. She holds a PhD in Chemical Engineering from the University of Cincinnati and has extensive experience in the biotechnology and medical device industries.
Work at Lyra Therapeutics
Maria Palasis serves as the President, CEO, and Board Director at Lyra Therapeutics since 2018. In this role, she leads the organization in developing innovative therapies for patients with chronic respiratory conditions. Her leadership has been instrumental in guiding the company's strategic direction and operational execution, contributing to its growth in the Greater Boston Area.
Current Roles at Other Organizations
In addition to her position at Lyra Therapeutics, Maria Palasis is also a Board Director at PanTher Therapeutics since 2020. She joined Beta Bionics as a member of the Advisory Board in 2022. Her involvement in these organizations reflects her commitment to advancing healthcare solutions and supporting innovative companies in the biotechnology sector.
Education and Expertise
Maria Palasis earned her Doctor of Philosophy (PhD) in Chemical Engineering from the University of Cincinnati - College of Engineering and Applied Science. Her educational background provides her with a strong foundation in engineering principles, which she applies throughout her career in the biotechnology and medical device industries.
Previous Experience in the Industry
Maria Palasis has extensive experience in the biotechnology field. She previously served as President and CEO of Arsenal Medical from 2015 to 2018 and held the position of Executive Vice President at the same company from 2008 to 2011. Additionally, she worked at Boston Scientific as Director of R&D for 13 years, from 1995 to 2008. Her diverse roles have equipped her with a comprehensive understanding of product development and organizational leadership.
Involvement with MedExecWomen
Maria Palasis was a member of the Advisory Board at MedExecWomen from 2018 to 2023. This role allowed her to contribute to initiatives aimed at supporting women in executive positions within the medical and biotechnology sectors, promoting diversity and inclusion in leadership roles.